Watch and Wait Strategy for Rectal Cancer: How Long Should We Wait for a Clinical Complete Response?


Journal

Surgical technology international
ISSN: 1090-3941
Titre abrégé: Surg Technol Int
Pays: United States
ID NLM: 9604509

Informations de publication

Date de publication:
19 May 2022
Historique:
pubmed: 29 1 2022
medline: 24 5 2022
entrez: 28 1 2022
Statut: ppublish

Résumé

The objective of this study was to determine how long to wait in locally advanced rectal tumor (LARC) patients who receive total neoadjuvant therapy (TNT) and achieve a clinical complete response (cCR), and to identify the clinical parameters that affect the waiting period for the watch-and-wait strategy (W &W). The data of patients who achieved cCR between February 2015 and June 2020 were examined retrospectively. The week in which patients with cCR at the end of TNT achieved clearance was determined by reanalyzing recorded endoscopy video images. In the assessment at the time of the initial diagnosis, tumor characteristics, such as digital rectal examination findings, MRI stage, location with respect to the puborectalis muscle, annularity, and tumor size, were recorded prospectively. A total of 54 patients were included in this study. According to the MRI-T stage, 14 cases were cT3a, 22 were cT3b, and 18 were cT3c-T4. Forty-four percent of the cases achieved cCR at 8-10 weeks, 19% at 12-16 weeks, 20% at 16-22 weeks, and 17% at 20-26 weeks. Patients with tumors that were early MRI-T stage (cT3a), negative clinical circumferential resection margin, mobile, small (≤4 cm), located above the puborectalis muscle and showed <180 degrees annularity achieved cCR significantly earlier than those with other tumors (p<0.05). In this study, cCR was achieved in less than half (44%) of the cases during the 8-10 week waiting period. In the W&W strategy, the initial assessment for cCR seems insufficient, and we may need to wait up to 26-30 weeks, especially in patients with advanced-stage tumors.

Sections du résumé

BACKGROUND BACKGROUND
The objective of this study was to determine how long to wait in locally advanced rectal tumor (LARC) patients who receive total neoadjuvant therapy (TNT) and achieve a clinical complete response (cCR), and to identify the clinical parameters that affect the waiting period for the watch-and-wait strategy (W &W).
MATERIALS AND METHODS METHODS
The data of patients who achieved cCR between February 2015 and June 2020 were examined retrospectively. The week in which patients with cCR at the end of TNT achieved clearance was determined by reanalyzing recorded endoscopy video images. In the assessment at the time of the initial diagnosis, tumor characteristics, such as digital rectal examination findings, MRI stage, location with respect to the puborectalis muscle, annularity, and tumor size, were recorded prospectively.
RESULTS RESULTS
A total of 54 patients were included in this study. According to the MRI-T stage, 14 cases were cT3a, 22 were cT3b, and 18 were cT3c-T4. Forty-four percent of the cases achieved cCR at 8-10 weeks, 19% at 12-16 weeks, 20% at 16-22 weeks, and 17% at 20-26 weeks. Patients with tumors that were early MRI-T stage (cT3a), negative clinical circumferential resection margin, mobile, small (≤4 cm), located above the puborectalis muscle and showed <180 degrees annularity achieved cCR significantly earlier than those with other tumors (p<0.05).
CONCLUSION CONCLUSIONS
In this study, cCR was achieved in less than half (44%) of the cases during the 8-10 week waiting period. In the W&W strategy, the initial assessment for cCR seems insufficient, and we may need to wait up to 26-30 weeks, especially in patients with advanced-stage tumors.

Identifiants

pubmed: 35090178
pii: sti40/1507
doi: 10.52198/22.STI.40.CR1507

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

130-139

Auteurs

Oktar Asoglu (O)

Bogazici Academy for Clinical Sciences of General Surgery, Istanbul, Turkey.

Beslen Goksoy (B)

Sehit Prof. Dr. Ilhan Varank Sancaktepe Training and Research Hospital University of Health Sciences, Department of General Surgery, Istanbul, Turkey.

Vusal Aliyev (V)

Acibadem Maslak Hospital, Department of General Surgery, Istanbul, Turkey.

Teuta Zoto Mustafayev (TZ)

Acibadem Maslak Hospital, Department of Radiation Oncology, Istanbul, Turkey.

Banu Atalar (B)

Acibadem University Maslak Hospital, Department of Radiation Oncology, Istanbul, Turkey.

Baris Bakir (B)

Istanbul University, Istanbul Faculty of Medicine, Department of Radiology, Istanbul, Turkey.

Koray Guven (K)

Acibadem University Maslak Hospital, Department of Radiology, Istanbul, Turkey.

Gokhan Demir (G)

Acibadem University Maslak Hospital, Department of Medical Oncology, Istanbul, Turkey.

Suha Goksel (S)

Acibadem Maslak Hospital, Department of Pathology, Istanbul, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH